Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00819052 · ClinicalTrials.gov registry record · Phase 3

Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

A Phase 3 study, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 3
Development phase
445
Enrollment target

NCT00819052: Completed Phase 3 study, sponsored by Boehringer Ingelheim.

NCT00819052 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 445 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00819052, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 3
Development phase
445 participants
Enrollment target

Study Summary

The primary objective of this study is to demonstrate the efficacy of nevirapine extended release (NVP XR) based regimen for HIV-1 infected patients who were receiving nevirapine immediate release (NVP IR) based regimen for at least 18 prior weeks of therapy.

Primary Outcome

Primary endpoint was the number of patients with a sustained virologic response through week 24

Interventions

  • DRUG Nevirapine XR
  • DRUG Nevirapine IR

Trial Details

FieldValue
Enrollment Target 445 participants
Start Date 2008-12
Est. Completion 2012-01
Phase Phase 3
Boehringer Ingelheim

515 total trials

What the finished NCT00819052 record still lists

NCT00819052 is an interventional study that assigns participants to a tested intervention. The registered 445 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).

The record links to 0 conditions, and to 2 interventions - of which Nevirapine XR is the first listed.

NCT00819052 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00819052 about?

NCT00819052 is a clinical study titled "Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients". The primary objective of this study is to demonstrate the efficacy of nevirapine extended release (NVP XR) based regimen for HIV-1 infected patients who were receiving nevirapine immediate release (NVP IR) based regimen for at least 18 prior weeks of therapy.

What is the current status of trial NCT00819052?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2008-12. Estimated completion is 2012-01.

What interventions are being tested in trial NCT00819052?

The interventions under investigation include: Nevirapine XR (DRUG), Nevirapine IR (DRUG).

Who is sponsoring clinical trial NCT00819052?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00819052's enrollment target sits among peer trials

445 864th of 2000 higher than 1,137 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01280994 · 445 participants · Phase 2

    Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

  • NCT03504800 · 445 participants

    OCT in Diagnosis of Irregular Corneas

  • NCT04751435 · 445 participants · NA

    Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

  • NCT06348394 · 444 participants · NA

    Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00819052, the US trial registry maintained by the National Library of Medicine. NCT00819052 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.